HXB2 Stock Overview
An immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
AIM ImmunoTech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.16 |
| 52 Week High | US$0.56 |
| 52 Week Low | US$0.13 |
| Beta | -0.36 |
| 11 Month Change | -19.00% |
| 3 Month Change | -41.73% |
| 1 Year Change | -53.71% |
| 33 Year Change | -87.14% |
| 5 Year Change | -55.03% |
| Change since IPO | -99.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| HXB2 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -8.5% | -0.7% | -0.02% |
| 1Y | -53.7% | -17.2% | 8.2% |
Return vs Industry: HXB2 underperformed the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: HXB2 underperformed the German Market which returned 8.2% over the past year.
Price Volatility
| HXB2 volatility | |
|---|---|
| HXB2 Average Weekly Movement | 16.8% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: HXB2's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: HXB2's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1966 | 27 | Thomas Equels | aimimmuno.com |
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company’s lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions.
AIM ImmunoTech Inc. Fundamentals Summary
| HXB2 fundamental statistics | |
|---|---|
| Market cap | €12.85m |
| Earnings (TTM) | -€22.98m |
| Revenue (TTM) | €182.46k |
70.4x
P/S Ratio-0.6x
P/E RatioIs HXB2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HXB2 income statement (TTM) | |
|---|---|
| Revenue | US$190.00k |
| Cost of Revenue | US$36.00k |
| Gross Profit | US$154.00k |
| Other Expenses | US$24.08m |
| Earnings | -US$23.93m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.38 |
| Gross Margin | 81.05% |
| Net Profit Margin | -12,594.21% |
| Debt/Equity Ratio | 93.8% |
How did HXB2 perform over the long term?
See historical performance and comparison